Abstract:Aim: High-sensitivity hybrid positron emission tomography (PET) imaging using advanced whole-body (WB) or total-body PET/computed tomography (CT) systems permits reducing injected tracer activity while preserving diagnostic quality. Such approaches are promising for healthy control studies or exploring inter-organ communication in systemic diseases. This study assessed test/retest variations in the fluoro-2-deoxy-D-glucose (FDG) uptake in key organs from low-dose (LD) and standard-dose (STD) [18F]FDG-PET/CT imaging protocols in healthy controls and lung cancer patients. Methods: A total of 19 healthy controls (19–62 years, 46–104 kg, 10 M/9 F) and 7 lung cancer patients (47–77 years, 50–88 kg, 4 M/3 F) underwent [18F]FDG-PET/CT imaging. All subjects were first injected ("test," LD) with 28 ± 2 MBq FDG and underwent a dynamic (0–67 min post-injection) WB imaging protocol with LD-CT. Then, 90 min post-LD injection, the subjects were repositioned and injected with 275 ± 16 MBq FDG ("retest," STD). Second LD-CT and STD-CT scans were acquired for healthy controls and patients, respectively. Static images (55–67 min post-injection) were considered for subsequent analysis. The CT images were used to automatically segment the target volumes of interest. Standardized uptake values normalized to the body weight (SUV BW ) were extracted for each volume of interest. The mean SUV BW were compared for both LD/STD conditions with paired t-tests. In patients, FDG-avid lesions were manually delineated on LD and STD static images. Effective dose levels were estimated from both the CT and PET acquisitions. Results: Organ-based mean SUV BW were similar between the LD and STD (mean %difference ≤5%) in both healthy controls and cancer patients, except in the heart. Intra-control test/retest variability was significant in the brain, heart, and skeletal muscle ( p < 0.05). While 17 lesions were delineated on the STD images of the patients, only 10/17 lesions were identified on the LD images due to increased image noise. Lesion-based mean SUV BW were similar between LD and STD acquisitions ( p = 0.49, %difference = 10%). In patients, the effective doses were (1.9 ± 0.2) mSv (LD-CT), (16.6 ± 5.4) mSv (STD-CT), (0.5 ± 0.1) mSv (LD-PET), and (4.6 ± 0.3) mSv (STD-PET). Conclusion: LD and STD [18F]FDG injections in healthy controls and lung cancer patients yielded comparable mean SUV BW , except in the heart. Dose levels may be reduced for [18F]FDG-PET imaging without a loss in mean SUV BW accuracy, promoting LD-PET/CT protocols for studying multi-organ metabolic patterns. In oncology patients, this approach may be hindered by a lower diagnostic quality in the presence of significant noise.

A PET/MRI study on the effect of obesity and NAFLD on hepatic [ 18 F]FDG uptake

Quantitative Evaluation of Hepatic Steatosis Using Novel Ultrasound Technology Normalized Local Variance (NLV) and Its Standard Deviation with Different ROIs in Patients with Metabolic-Associated Fatty Liver Disease: a Pilot Study.

The combined effects of serum lipids, BMI, and fatty liver on 18F-FDG uptake in the liver in a large population from China: an 18F-FDG-PET/CT study.

Free-breathing liver fat quantification using a multiecho 3D stack-of-radial technique.

F-FDG uptake in the liver in a large population from China: an F-FDG-PET/CT study

Novel approach using [18F]FTHA-PET and de novo synthesized VLDL for assessment of FFA metabolism in a rat model of diet induced NAFLD

Low-dose and standard-dose whole-body [18F]FDG-PET/CT imaging: implications for healthy controls and lung cancer patients

18F-FDG Assessment of Hepatic Glucose Uptake in Nonalcoholic Fatty Liver Disease Patients

Effect of Blood Pool 18F-FDG Activity on Liver SUV: a Calibration Methodology Study

Variations of the Liver Standardized Uptake Value in Relation to Background Blood Metabolism: an 2-[F-18]fluoro-2-deoxy-d-glucose Positron Emission Tomography/computed Tomography Study in a Large Population from China

Combined impacts of blood glucose level and glucose metabolism-related factors on liver 18F-FDG uptake

Quantitative Assessment of Intrahepatic Fat Content in Children and Adolescents with Non-Alcoholic Fatty Liver Disease

Optimized Dose Regimen of 18F-FDG Total Body PET/CT Imaging in Oncological Patients

Variations of 18F-Fluorodeoxyglucose Uptake of Pancreas in Healthy Subjects and the Influential Factors

Effects of blood glucose level on 18F fluorodeoxyglucose (18F-FDG) uptake for PET/CT in normal organs: an analysis on 5623 patients

Effects of blood glucose level on 18F-FDG uptake for PET/CT in normal organs: A systematic review

Variations of the Liver Standardized Uptake Value in Relation to Background Blood Metabolism

Variability and Reliability of Normal Liver 18F-FDG Standardized Uptake Value in Relation to Placement of Volume of Interest

Non-specific uptake of 18F-FAPI-04 in the pancreas and its related factors: a post-hoc analysis of an ongoing prospective clinical trial

Ultrasound-Derived Fat Fraction for Hepatic Steatosis Assessment: Prospective Study of Agreement With MRI PDFF and Sources of Variability in a Heterogeneous Population

The Association between the Body Mass Index, Chronic Obstructive Pulmonary Disease and SUV of the Non-Tumorous Lung in the Pretreatment [18F]FDG-PET/CT of Patients with Lung Cancer